Baozun (BZUN) Gets BidaskScore Lower Rating; Myriad Genetics (MYGN)’s Sentiment Is 0.98

Myriad Genetics, Inc. (NASDAQ:MYGN) Logo

Trading of Baozun (NASDAQ:BZUN)‘s shares is going to be interesting today as BidaskScore cut the stock to a Sell.

Myriad Genetics Inc (MYGN) investors sentiment decreased to 0.98 in 2019 Q3. It’s down -0.10, from 1.08 in 2019Q2. The ratio dived, as 91 institutional investors opened new or increased equity positions, while 93 cut down and sold positions in Myriad Genetics Inc. The institutional investors in our database reported: 76.00 million shares, down from 77.57 million shares in 2019Q2. Also, the number of institutional investors holding Myriad Genetics Inc in top ten equity positions increased from 0 to 2 for an increase of 2. Sold All: 28 Reduced: 65 Increased: 61 New Position: 30.

Tieton Capital Management Llc holds 4.19% of its portfolio in Myriad Genetics, Inc. for 171,834 shares. Kestrel Investment Management Corp owns 229,925 shares or 3.27% of their US portfolio. Moreover, S&T Bank Pa has 2.07% invested in the company for 328,343 shares. The Minnesota-based Disciplined Growth Investors Inc Mn has invested 1.47% in the stock. Glenview Capital Management Llc, a New York-based fund reported 3.68 million shares.

More notable recent Myriad Genetics, Inc. (NASDAQ:MYGN) news were published by: Globenewswire.com which released: “Myriad’s Polygenic Risk Score Personalizes Risk of Breast Cancer for Woman with a Genetic Mutation in Important Breast Cancer Genes – GlobeNewswire” on December 14, 2019, also Finance.Yahoo.com with their article: “Myriad Shareholder Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Myriad Genetics, Inc. To Contact The Firm – Yahoo Finance” published on November 25, 2019, Nasdaq.com published: “Myriad Genetics (MYGN) Q1 Earnings and Revenues Miss Estimates – Nasdaq” on November 04, 2019. More interesting news about Myriad Genetics, Inc. (NASDAQ:MYGN) were released by: Globenewswire.com and their article: “MYGN FINAL DEADLINE: ROSEN LAW FIRM Reminds Myriad Genetics, Inc. Investors of Tuesday Deadline in Securities Class Action – MYGN – GlobeNewswire” published on November 25, 2019 as well as Finance.Yahoo.com‘s news article titled: “Myriad’s Prequelâ„¢ Prenatal Screen has Superior Sensitivity in Women with High BMI Undergoing Non-Invasive Prenatal Screening – Yahoo Finance” with publication date: December 04, 2019.

Myriad Genetics, Inc., a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company has market cap of $1.90 billion. The firm offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BART, a DNA sequencing test for hereditary breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents. It currently has negative earnings. It also provides COLARIS, a DNA sequencing test for colorectal and uterine cancer; COLARIS AP, a DNA sequencing test for colorectal cancer; Vectra DA, a protein quantification test for assessing the disease activity of rheumatoid arthritis; Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer; and EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer.

The stock increased 2.32% or $0.58 during the last trading session, reaching $25.58. About 532,910 shares traded. Myriad Genetics, Inc. (MYGN) has declined 20.29% since December 15, 2018 and is downtrending. It has underperformed by 20.29% the S&P500. Some Historical MYGN News: 08/05/2018 – MYRIAD GENETICS 3Q REV. $193.5M, EST. $187.5M; 15/05/2018 – Myriad Genetics to Present Eight Studies at the 2018 American Society of Clinical Oncology Annual Meeting; 15/03/2018 – Scott+Scott Attorneys at Law LLP Announces Investigation into Myriad Genetics, Inc. (MYGN); 11/05/2018 – The Klein Law Firm Reminds Investors of a Class Action Commenced on Behalf of Myriad Genetics, Inc. Shareholders and a Lead Plaintiff Deadline of June 19, 2018; 08/05/2018 – The Klein Law Firm Announces a Class Action Filed on Behalf of Myriad Genetics, Inc. Shareholders and a Lead Plaintiff Deadline; 07/05/2018 – MYRIAD SAYS GENESIGHT USE SHOWED 50% IMPROVEMENT MDD REMISSION; 04/05/2018 – Myriad Genetics to Present Five Studies at the Seventh International Symposium on Hereditary Breast and Ovarian Cancer; 12/03/2018 – MYRIAD GENETICS – NO CLAIMS HAVE BEEN MADE AGAINST CO AT THIS TIME; 08/05/2018 – The Klein Law Firm Announces a Class Action Commenced on Behalf of Myriad Genetics, Inc. Shareholders and a Lead Plaintiff; 19/03/2018 – Glancy Prongay & Murray LLP Continues Investigation on Behalf of Myriad Genetics, Inc. Investors (MYGN)

Analysts await Myriad Genetics, Inc. (NASDAQ:MYGN) to report earnings on February, 4. They expect $0.23 EPS, down 23.33% or $0.07 from last year’s $0.3 per share. MYGN’s profit will be $17.08M for 27.80 P/E if the $0.23 EPS becomes a reality. After $-0.03 actual EPS reported by Myriad Genetics, Inc. for the previous quarter, Wall Street now forecasts -866.67% EPS growth.

More notable recent Baozun Inc. (NASDAQ:BZUN) news were published by: Seekingalpha.com which released: “Baozun: Questionable Outlook Rings The Bell – Seeking Alpha” on December 13, 2019, also Nasdaq.com with their article: “Baozun’s (BZUN) Earnings and Revenues Improve Y/Y in Q3 – Nasdaq” published on November 25, 2019, Nasdaq.com published: “Why Baozun Stock Fell Sharply Thursday – Nasdaq” on November 21, 2019. More interesting news about Baozun Inc. (NASDAQ:BZUN) were released by: Nasdaq.com and their article: “Why Baozun Stock Lost 13% Last Month – Nasdaq” published on December 02, 2019 as well as Nasdaq.com‘s news article titled: “Consumer Sector Update for 11/21/2019: BJ, BZUN, TIF, WMT, MCD, DIS, CVS, KO – Nasdaq” with publication date: November 21, 2019.

Among 4 analysts covering Baozun (NASDAQ:BZUN), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Baozun has $59.2000 highest and $3800 lowest target. $46.93’s average target is 34.12% above currents $34.99 stock price. Baozun had 6 analyst reports since August 5, 2019 according to SRatingsIntel. The rating was maintained by Bank of America with “Buy” on Monday, August 26. The firm has “Neutral” rating by Credit Suisse given on Friday, November 22.

Myriad Genetics, Inc. (NASDAQ:MYGN) Institutional Positions Chart